Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, KAI-9531
K9531-3107
Phase 3 small_molecule active
Quick answer
Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, KAI-9531 for Obesity is a Phase 3 program (small_molecule) at Kailera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kailera Therapeutics
- Indication
- Obesity
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active